Sign in
Taking peoplePhase 2

A Study of Aztreonam-Avibactam (ATM-AVI) Compared to Best Available Therapy in Pediatric Participants with Serious Gram-Negative Bacterial Complicated Intra-abdominal, Complicated Urinary Tract, Blood Stream Infections, and Hospital Acquired and Ventilator Associated Pneumonia

Key facts

Who runs it
Pfizer Inc.
Where
Czechia, Greece, Hungary, and Spain12 sites in 4 countriesChoose a country to see its sites
Status
Recruiting
Phase
Phase 2
People taking part
20 people, planned
Started
24 Apr 2023
Expected to end
31 Mar 2027
Type of study
Interventional
Record updated
16 September 2026

Who can take part

Age
Up to 17 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Participants ≥9 months to <18 years of age at Screening; Female (post-menarchal) participants must have a negative serum/urine pregnancy test (βhCG sensitivity ≥25 mIU/mL)
  • Suspected/confirmed cIAI, cUTI, HAP/VAP, or BSI with gram-negative pathogens
  • Require hospitalization and IV antibiotic treatment

Who cannot take part

  • Previous enrollment in the study
  • Received >24 hours of systemic antibiotics during the 48 hours before randomization unless participant has documented treatment failure after at least 48 hours of antibiotic therapy
  • Current use of any prohibited concomitant medication(s) or unwilling/unable (Cockayne Syndrome patients with cIAI are excluded) to use MTZ or having received previous investigational drug(s) or vaccine ≤30 days or 5 half-lives before randomization (whichever is longer)
  • (HAP/VAP only): Microbiologically known or high likelihood of monomicrobial infection with a gram-positive organism, lung abscess, pleural empyema, or postobstructive pneumonia, lung or heart transplant
  • Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator’s judgment, make the participant inappropriate for the study
  • CrCL ≤15 mL/min/1.73 m2 (eCrCl or eGFR calculation based on age)
  • Non-infectious related screening ALT or AST >3 x ULN, ALP >3 x ULN and/or TBili >2 x ULN (> 3 x ULN for Gilbert’s syndrome)
  • Gram-negative species not expected to respond to ATM-AVI ≤14 days
  • Pregnant or breastfeeding; fertile male/female unwilling/unable to use effective contraception for at ≥7 days (males) or ≥28 days (females) after last ATM-AVI infusion
  • Investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members

This trial is currently available in Greece, Hungary, and Spain.

It has sites in 4 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

Evaluate the PK of ATM-AVI for the treatment of serious gram-negative bacterial infections in participants 9 months to <18 years of age. Evaluate the safety, and tolerability of ATM-AVI and BAT for the treatment of serious gram-negative bacterial infections in participants 9 months to <18 years of age.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
C3601008 - A PHASE 2A MULTICENTER, OBSERVER-BLINDED, RANDOMIZED 2 ARM STUDY TO INVESTIGATE PHARMACOKINETICS, SAFETY, TOLERABILITY AND EFFICACY OF INTRAVENOUS AZTREONAM-AVIBACTAM ± METRONIDAZOLE COMPARED TO BEST AVAILABLE THERAPY (BAT) IN PEDIATRIC PARTICIPANTS 9 MONTHS TO LESS THAN 18 YEARS OF AGE WITH SERIOUS GRAM-NEGATIVE BACTERIAL INFECTIONS INCLUDING COMPLICATED INTRA-ABDOMINAL INFECTION
Record updated
16 September 2026